Cell and gene therapy

Advanced Therapies Week
#Advanced Therapies #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Events

ATW reveals five big shifts for cell and gene therapy

Phacilitate’s 22nd Advanced Therapies Week (ATW) took place in San Diego on 9-12 February, bringing together industry stakeholders from around the world for to showcase progress in cell and gene therapies (CGT).   From manufacturing bottlenecks and regulatory transparency to the rise of in vivo… Read More

#Editor's Choice #Editor's Pick #News

#AbbVie #Cell and gene therapy #CRISPR Therapeutics #Eli Lilly #Hansa Biopharma #Resolution Therapeutics #Vertex

Cell and gene therapies – looking forward

Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More

#Exclusive Content

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

2026 ideas
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #Gene editing

CGT in 2026: In vivo, greater specificity and next-gen platforms

What does the coming year hold for advanced therapies? Diana Turner asks industry leaders for their predictions for 2026. 2025 was a mixed year for cell and gene therapies (CGT) with some incredible breakthroughs, but also a withdrawal of many companies from their cell therapy programmes. Read More

#Exclusive Content #Trends & Analysis

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

Conference microphone
#Cell and gene therapy #ELRIG #UK

ELRIG announces keynote speakers for CGT conference 

ELRIG has announced Dr Stephen Ward and Dr Annarita Miccio as keynote speakers for its Cell and Gene Therapy event in March.  The not-for-profit organisation aims to bring together leading scientists, economists and patient advocates to explore breakthroughs shaping the future of medicine.   The programme, focussing on… Read More

#News

T cells
#Advanced Therapies #Atara #Cell and gene therapy #Cell therapy #FDA #Pierre Fabre Laboratories

FDA rejects second application for off-the-shelf T-cell therapy

The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf” allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA).  The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the… Read More

#News #Regulatory

#Cell and gene therapy #Gene editing #Immunotherapy #Neurodegenerative disorders #Obesity #Oncology

Which drug discovery breakthroughs made the headlines in 2025?

Diana Turner counts down the biggest DDW news stories of 2025.  10. First use of CAR-T therapy to treat ulcerative colitis In October, a team of physicians at the German Center for Immunotherapy at Erlangen University Hospital succeeded for the first time in treating a… Read More

#Exclusive Content

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

Woman reading on a laptop
#CAR-T #Cell and gene therapy #Flow Cytometry #Oncology #Quantum computing

Your top reads of 2025

With topics as diverse as quantum computing, ion channel drug discovery and antisense oligonucleotides, these were DDW readers’ most-read articles of 2025.  10. We need international partnerships to get new cancer drugs into the clinic On International Clinical Trials Day, Lars Erwig, Director of the… Read More

#Exclusive Content

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

Cell and gene therapy concept
#Cell and gene therapy #Charles River #Drug discovery

Charles River to support companies developing therapeutics 

Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP).  The CIP cohort includes six companies, four of which are advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics and Kopra Bio) and two enabling technology… Read More

#News

#Advanced Therapies #Cell and gene therapy #FDA #Gene therapy #Rare disease

FDA approves first gene therapy for Wiskott-Aldrich syndrome

The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene… Read More

#Editor's Choice #News #Regulatory

#Advanced Therapies #Cell and gene therapy #GlobalData #Investment

Investment shifting in cell and gene therapy, report reveals 

Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds.  According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape.  While venture… Read More

#Business & Investment #News

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug development #NHS

eXmoor and NHS trust partner on cell & gene therapies 

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which… Read More

#Business & Investment #News